BALAXI PHARMACEUTICALS LIMITED — Others, 05-08-2025: Statement of deviation(s) or variation(s) under Reg. 32

Balaxi Pharmaceuticals has provided an update on the use of funds from its preferential issue. For the quarter ended June 30, 2025, the company confirmed no deviation in how the 47.57 Cr raised is being utilised. Out of the total, 28.63 Cr has been used so far. These funds are earmarked for critical capital expenditure related to the new pharmaceutical formulation plant, along with supporting working capital needs and general corporate purposes. This update assures investors the company is on track with its financing plans and deployment of capital for growth.